Long-Term Efficacy of Adjunctive Cariprazine in Patients With MDD: Results From an Open-Label 26-Week Safety Study

被引：0
|
作者：
Masand, Prakash [1 ]
Vieta, Eduard [1 ]
Waraich, Simranpreet [1 ]
Kramer, Ken [1 ]
Kerolous, Majid [1 ]
机构：
[1] AbbVie, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2023年 / 48卷
关键词：
Cariprazine; Major Depressive Disorder; Depression; Adjunctive; Long-Term;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P343
引用
收藏
页码：263 / 264
页数：2
相关论文
共 50 条
  • [1] Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
    Nelson, Craig
    Skuban, Aleksandar
    Zhang, Peter
    Weiller, Emmanuelle
    Weiss, Catherine
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 103 - 103
  • [2] Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study
    Higuchi, Teruhiko
    Ishigooka, Jun
    Iyo, Masaomi
    Hagi, Katsuhiko
    ASIA-PACIFIC PSYCHIATRY, 2020, 12 (01)
  • [3] Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study
    Cutler, Andrew J.
    Durgam, Suresh
    Wang, Yao
    Migliore, Raffaele
    Lu, Kaifeng
    Laszlovszky, Istvan
    Nemeth, Gyorgy
    CNS SPECTRUMS, 2018, 23 (01) : 39 - 50
  • [4] Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
    Tepper, Stewart J.
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan Lewis
    Dolezil, David
    Silberstein, Stephen D.
    Winner, Paul
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel D.
    CEPHALALGIA, 2020, 40 (06) : 543 - 553
  • [5] A 26-week, Open-label Extension Study Evaluating The Long-term Safety And Tolerability Of Ciclesonide Hydrofluoroalkane Nasal Aerosol In Patients With Perennial Allergic Rhinitis
    Storms, W.
    Gross, G.
    Spector, S.
    Huang, H.
    Desai, S. Y.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB191 - AB191
  • [6] Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder
    Ketter, T. A.
    Sachs, G. S.
    Lu, K.
    Ruth, A.
    Laszlovszky, I.
    Nagy, K.
    Starace, A.
    Durgam, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S377 - S377
  • [7] Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures
    Klein, Pavel
    Aboumatar, Sami
    Brandt, Christian
    Dong, Fang
    Krauss, Gregory L.
    Mizne, Sarah
    Sanchez-Alvarez, Juan Carlos
    Steinhoff, Bernhard J.
    Villanueva, Vicente
    NEUROLOGY, 2022, 99 (10) : E989 - E998
  • [8] Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder
    Ketter, T. A.
    Sachs, G.
    Lu, K.
    Laszlovszky, I.
    Nagy, K.
    Starace, A.
    Durgam, S.
    BIPOLAR DISORDERS, 2013, 15 : 134 - 134
  • [9] Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
    Suresh Durgam
    William M. Greenberg
    Dayong Li
    Kaifeng Lu
    Istvan Laszlovszky
    Gyorgy Nemeth
    Raffaele Migliore
    Stephen Volk
    Psychopharmacology, 2017, 234 : 199 - 209
  • [10] Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
    Durgam, Suresh
    Greenberg, William M.
    Li, Dayong
    Lu, Kaifeng
    Laszlovszky, Istvan
    Nemeth, Gyorgy
    Migliore, Raffaele
    Volk, Stephen
    PSYCHOPHARMACOLOGY, 2017, 234 (02) : 199 - 209
12345